Professor Sinead Delany-Moretlwe is the Director of Research at Wits RHI and Professor of Global Health and Infectious Diseases at the University of the Witwatersrand, Johannesburg. Her research interests span the intersections between sexual and reproductive health (SRH) and infectious diseases. She has been an investigator on several phase III trials of new HIV prevention technologies and was protocol chair of the landmark trial for cabotegravir as injectable PrEP for women, which led licensure of cabotegravir for PrEP in several countries including Australia. With respect to HPV, she has led several studies investigating approaches to HPV screening and vaccination in people living with HIV. She is currently the chief investigator of an NHMRC-funded population impact study of one and two doses of HPV vaccination in South Africa. Her current focus includes the evaluation of strategies for the prevention and control of curable STIs including trials of new treatments and vaccines for gonorrhoea. She works with an extensive network of local and international collaborators and is also an advisor on several South African and WHO advisory committees, including the WHO PDVAC committee, and the WHO HIV, Hepatitis and STIs Scientific and Technical Advisory Committee. Prof Delany-Moretlwe has also been appointed as a co-principal investigator for the groundbreaking HIV Prevention Trials Network (HPTN).
